Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;7(Suppl 2):S69.
doi: 10.21037/atm.2019.02.48.

Current anti-copper therapies in management of Wilson disease

Isabelle Mohr  1 , Karl Heinz Weiss  1
Affiliations
Review

Current anti-copper therapies in management of Wilson disease

Isabelle Mohr et al. Ann Transl Med. 2019 Apr.

Abstract

In Wilson disease (WD) severity of disease can vary widely, depending on time of diagnosis. Early treatment can prevent the development of symptoms in patients. In all patients, lifelong medical treatment is indicated. Currently available medical regimens include the copper chelators for example D-penicillamine (DPA) or trientine (TETA), acting to increase copper excretion and zinc salts (ZS), which reduce copper uptake. In this chapter, we discuss considerations regarding choice of drug and safety limitations.

Keywords: D-penicillamine (DPA); Trientine (TETA); anti-copper-drugs; zinc.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: KH Weiss advises or received grant support from for GMP-O, Univar, Vivet therapeutics, Alexion. I Mohr has no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Walshe JM. History of Wilson's disease: 1912 to 2000. Mov Disord 2006;21:142-7. 10.1002/mds.20694 - DOI - PubMed
    1. Walshe JM. History of Wilson disease: a personal account. Handb Clin Neurol 2017;142:1-5. 10.1016/B978-0-444-63625-6.00001-X - DOI - PubMed
    1. Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet Neurol 2015;14:103-13. 10.1016/S1474-4422(14)70190-5 - DOI - PMC - PubMed
    1. Członkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers 2018;4:21. 10.1038/s41572-018-0018-3 - DOI - PMC - PubMed
    1. European Association for Study of L. EASL Clinical Practice Guidelines : Wilson’s disease. J Hepatol 2012;56:671-85. - PubMed